GO:0009150 purine ribonucleotide metabolic process: Nucleotide Biosynthesis Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0009150 describes the chemical reactions and pathways involving purine ribonucleotides, which are purine bases linked to ribose sugar and esterified with phosphate at the 3' or 5' hydroxyl group.
• De novo purine biosynthesis is a highly conserved, energy-intensive pathway that builds the purine ring atom by atom on ribose-5-phosphate, requiring multiple enzymatic steps and cofactors.
• Purine ribonucleotide metabolism is essential for DNA and RNA synthesis, energy currency (ATP/GTP), and signaling molecules (cAMP, cGMP), making it central to cell proliferation and survival.
• Dysregulation of purine biosynthesis is implicated in cancer, inflammatory diseases, and myogenic hyperuricemia, with key enzymes such as ATIC and PAICS as potential therapeutic targets.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable precise dissection of purine metabolic gene function in disease contexts.
• Targeting the purinome, including purine metabolic enzymes, offers broad opportunities for drug discovery and precision medicine.
Description
Purine ribonucleotide metabolic process (GO:0009150) encompasses the chemical reactions and pathways involving purine ribonucleotides, which are compounds consisting of a purine base linked to a ribose sugar and esterified with a phosphate group at either the 3' or 5' hydroxyl group of the sugar. This process is fundamental to all living cells, providing the building blocks for DNA and RNA, as well as key energy carriers and signaling molecules. Researchers study this pathway to understand how cells maintain nucleotide pools, respond to metabolic stress, and how its dysregulation contributes to diseases such as cancer and inflammatory disorders. The de novo purine biosynthesis pathway, a core component of GO:0009150, is a highly conserved and energy-intensive process that has been extensively characterized at the structural and mechanistic level. Recent advances in CRISPR gene editing have enabled precise manipulation of genes involved in purine ribonucleotide metabolism, facilitating functional studies and drug target validation. This article provides a comprehensive overview of the ontology, mechanisms, key genes, disease relevance, and research methods associated with GO:0009150.
purine ribonucleotide metabolic process At A Glance
| GO ID | GO:0009150 |
|---|---|
| GO term | purine ribonucleotide metabolic process |
| Ontology | biological_process |
| Synonym | purine ribonucleotide metabolism |
| Definition | The chemical reactions and pathways involving a purine ribonucleotide, a compound consisting of ribonucleoside (a purine base linked to a ribose sugar) esterified with a phosphate group at either the 3' or 5' hydroxyl group of the sugar. |
| Major function | Synthesis and interconversion of purine ribonucleotides (AMP, GMP, IMP) for nucleic acid synthesis, energy metabolism, and signaling. |
| Key pathways | De novo purine biosynthesis, salvage pathways, and interconversion pathways. |
| Cellular location | Cytosol and mitochondria (de novo pathway enzymes are cytosolic; some steps in mitochondria). |
| Related diseases | Cancer, inflammatory diseases, myogenic hyperuricemia, and metabolic disorders. |
What Is GO:0009150?
GO:0009150, purine ribonucleotide metabolic process, is defined as the chemical reactions and pathways involving a purine ribonucleotide, a compound consisting of a ribonucleoside (a purine base linked to a ribose sugar) esterified with a phosphate group at either the 3' or 5' hydroxyl group of the sugar. In simpler terms, it covers all the steps by which cells build, modify, and break down purine nucleotides such as AMP, GMP, IMP, and their derivatives, which are essential for nucleic acid synthesis, energy transfer, and cellular signaling.
Why Is purine ribonucleotide metabolic process Important in Cell Biology?
Purine ribonucleotide metabolism is essential for cell growth, proliferation, and survival because it supplies the building blocks for DNA and RNA and maintains the energy currency ATP and GTP. Dysregulation of this pathway is a hallmark of many cancers, where rapidly dividing cells have increased demand for nucleotides, and it also plays a critical role in immune cell activation and inflammatory responses. Understanding the molecular details of purine ribonucleotide metabolism provides opportunities for therapeutic intervention, as evidenced by the development of inhibitors targeting enzymes such as N5-CAIR mutase and the recognition of ATIC as a regulator of muscle atrophy. Moreover, inherited defects in purine metabolism cause disorders like myogenic hyperuricemia, highlighting its clinical importance.
• Provides precursors for DNA and RNA synthesis, essential for cell division and growth.
• Maintains cellular energy homeostasis through ATP and GTP production.
• Generates signaling molecules such as cAMP and cGMP that regulate diverse cellular processes.
• Supports immune cell function and inflammatory responses by supplying nucleotides for proliferation.
• Dysregulated in cancer, making pathway enzymes attractive drug targets.
• Involved in muscle metabolism and myogenic hyperuricemia, linking purine metabolism to exercise and muscle wasting.
• Subject to complex regulation by acetylation and other post-translational modifications, as shown for PAICS.
• Targeted by small-molecule inhibitors, offering potential for therapeutic development.
• Can be studied using CRISPR knockout models to uncover gene function in vivo.
• Represents a paradigm for understanding metabolic pathway compartmentalization and channeling.
What Happens During purine ribonucleotide metabolic process?
De Novo Purine Biosynthesis
In simple terms: Cells build purine rings from scratch using simple molecules like amino acids and sugars.
De novo purine biosynthesis is a ten-step enzymatic pathway that assembles the purine ring on ribose-5-phosphate, consuming ATP and other cofactors. Key enzymes include PRPP synthetase, GART, PFAS, PAICS, ADSL, and ATIC, which catalyze the sequential addition of atoms to form inosine monophosphate (IMP). This pathway is highly conserved and energetically expensive, requiring multiple ATP molecules per IMP produced. Recent structural and mechanistic studies have elucidated the roles of carboxylation and other chemical steps in this pathway.
Interconversion of Purine Ribonucleotides
In simple terms: Cells convert one type of purine nucleotide into another to meet changing needs.
IMP serves as the central branch point for the synthesis of AMP and GMP. IMP is converted to AMP via adenylosuccinate synthetase and lyase, and to GMP via IMP dehydrogenase and GMP synthetase. These interconversion reactions are feedback-regulated by the end products to balance purine pools. The enzymes involved, such as ADSL and IMPDH, are critical for maintaining nucleotide homeostasis and are often dysregulated in cancer.
Salvage Pathways
In simple terms: Cells recycle purine bases from degraded nucleotides to save energy.
Salvage pathways recover purine bases (adenine, guanine, hypoxanthine) from nucleic acid turnover and convert them back to nucleotides using enzymes like APRT, HPRT, and adenine/guanine phosphoribosyltransferases. These pathways are more energy-efficient than de novo synthesis and are essential in tissues with high nucleotide turnover, such as the brain and immune cells. Defects in salvage enzymes cause severe disorders, including Lesch-Nyhan syndrome (HPRT deficiency).
Regulation by Post-Translational Modifications
In simple terms: Chemical tags on enzymes can switch purine production on or off.
Recent studies have shown that purine biosynthetic enzymes are regulated by acetylation and other modifications. For example, ACSS2 drives the senescence-associated secretory phenotype by limiting purine biosynthesis through acetylation of PAICS, leading to reduced flux through the pathway. This highlights a layer of metabolic control that integrates cellular stress and metabolic state with nucleotide production.
Compartmentalization and Channeling
In simple terms: Enzymes in the pathway often work together in complexes to pass products efficiently.
Many de novo purine biosynthesis enzymes form multienzyme complexes (purinosomes) that channel intermediates, enhancing pathway efficiency. This spatial organization allows cells to respond rapidly to changes in demand and may be disrupted in disease. Understanding channeling mechanisms is an active area of research with implications for drug design.
Key Genes Involved in GO:0009150 purine ribonucleotide metabolic process
The following genes encode key enzymes and regulators involved in purine ribonucleotide metabolic process (GO:0009150), with their major roles and relevance to research.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PPAT | Catalyzes the first step of de novo purine biosynthesis, converting PRPP to PRA | Target for metabolic studies and inhibitor development |
| GART | Trifunctional enzyme with GARS, AIRS, and GART activities in de novo pathway | Mutations cause severe neurological disorders; model for pathway defects |
| PFAS | Catalyzes two steps in de novo purine biosynthesis (FGAM synthetase and AIR synthetase) | Target for anticancer drug discovery |
| PAICS | Bifunctional enzyme with AIR carboxylase and SAICAR synthetase activities | Regulated by acetylation; linked to senescence and cancer |
| ADSL | Catalyzes the conversion of SAICAR to AICAR in de novo pathway | Deficiency causes adenylosuccinate lyase deficiency; model for neurodevelopmental disorders |
| ATIC | Bifunctional enzyme with AICAR transformylase and IMP cyclohydrolase activities | Knockout in zebrafish affects muscle atrophy and exercise response |
| IMPDH1/2 | Catalyzes the conversion of IMP to XMP in GMP synthesis | Target of immunosuppressive drugs; overexpressed in cancer |
| GMPS | Catalyzes the final step of GMP synthesis from XMP | Potential target in cancer and viral infections |
| ADSS1/2 | Catalyzes the conversion of IMP to adenylosuccinate in AMP synthesis | Linked to muscle metabolism and myogenic hyperuricemia |
| APRT | Salvage enzyme converting adenine to AMP | Deficiency causes kidney stones; model for purine salvage defects |
| HPRT1 | Salvage enzyme converting hypoxanthine to IMP | Deficiency causes Lesch-Nyhan syndrome; key model for purine metabolism |
| PRPS1/2 | Catalyzes PRPP synthesis, a rate-limiting step in purine biosynthesis | Mutations cause PRPS1 superactivity and gout; drug target |
| ACSS2 | Regulates purine biosynthesis via PAICS acetylation | Links acetate metabolism to purine pathway; target for senescence research |
| ATIC | See above | See above |
| PAICS | See above | See above |
| ADSL | See above | See above |
| GART | See above | See above |
| PFAS | See above | See above |
How Is purine ribonucleotide metabolic process Regulated?
Purine ribonucleotide metabolism is regulated at multiple levels, including feedback inhibition by end products (AMP, GMP) on early enzymes, transcriptional control, and post-translational modifications. For instance, acetylation of PAICS by ACSS2 reduces purine biosynthesis, linking metabolic state to pathway activity. Additionally, the pathway is subject to regulation by mTOR signaling, which promotes nucleotide synthesis to support cell growth, and by the integrated stress response under nutrient limitation. These regulatory mechanisms ensure that purine production matches cellular demand and are often hijacked in cancer cells to sustain proliferation.
purine ribonucleotide metabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ATIC | Muscle atrophy and hyperuricemia | Zebrafish knockout and exercise intervention |
| PAICS | Cancer and senescence-associated secretory phenotype | Cancer cell lines with PAICS acetylation mutants |
| ADSL | Adenylosuccinate lyase deficiency (neurodevelopmental disorder) | Patient-derived iPSCs and knock-in mouse models |
| HPRT1 | Lesch-Nyhan syndrome | HPRT knockout mice and cell lines |
| IMPDH1 | Retinitis pigmentosa and cancer | Retinal organoids and xenograft models |
Cancer
Many cancers exhibit upregulated de novo purine biosynthesis to meet the high demand for nucleotides during rapid proliferation. Enzymes such as PAICS, ATIC, and IMPDH are overexpressed in various tumors and correlate with poor prognosis. Targeting these enzymes with inhibitors or CRISPR knockout reduces tumor growth in preclinical models, making the pathway a promising therapeutic target.
Inflammatory and Immune Disorders
Purine release and metabolism play a critical role in the inflammatory response. Extracellular ATP and adenosine act as danger signals and regulators of immune cell function, and purine metabolic enzymes modulate the balance between pro- and anti-inflammatory signals. Dysregulation contributes to autoimmune diseases and chronic inflammation, and targeting purinergic signaling is an active area of drug development.
Myogenic Hyperuricemia and Muscle Metabolism
Defects in purine metabolism, particularly in the salvage and interconversion pathways, can lead to myogenic hyperuricemia, characterized by excessive uric acid production during exercise. Studies in ATIC knockout zebrafish show that aerobic exercise ameliorates skeletal muscle atrophy through oxidative phosphorylation, linking purine metabolism to muscle health. This highlights the importance of purine enzymes in muscle energy homeostasis.
Neurodevelopmental Disorders
Inherited mutations in purine biosynthesis genes, such as ADSL and GART, cause severe neurodevelopmental disorders including adenylosuccinate lyase deficiency and GART deficiency, which present with intellectual disability, seizures, and autism. These rare diseases underscore the critical role of purine metabolism in brain development and function.
From purine ribonucleotide metabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ATIC affect muscle atrophy and exercise capacity? | ATIC knockout zebrafish |
| How does PAICS acetylation regulate purine biosynthesis in senescence? | PAICS point-mutation knock-in cell lines |
| Can CRISPR knockout of IMPDH reduce tumor growth? | Xenograft mouse models with IMPDH knockout cancer cells |
| What is the role of ADSL in neurodevelopment? | ADSL knockout mice and patient iPSC-derived neurons |
| Does overexpression of PRPS1 cause gout? | Transgenic mouse models with PRPS1 overexpression |
| How does HPRT deficiency lead to Lesch-Nyhan syndrome? | HPRT knockout mice and cell lines |
How to Study the purine ribonucleotide metabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS metabolomics | Levels of purine nucleotides and intermediates | Quantifying pathway activity in cells |
| 13C isotope tracing | Flux through de novo purine biosynthesis | Assessing pathway contribution to nucleotide pools |
| CRISPR knockout screens | Gene essentiality and synthetic lethality | Identifying new targets in cancer |
| Enzyme activity assays | Catalytic rate of purine enzymes | Screening inhibitors |
| X-ray crystallography | Three-dimensional structures of enzymes | Structure-guided drug design |
| RNA-seq | Transcriptional changes in purine genes | Profiling pathway expression |
| Proteomics | Protein abundance and modifications | Detecting acetylation of PAICS |
| Zebrafish models | In vivo effects of gene knockout on muscle | Studying exercise and atrophy |
Metabolomics and Flux Analysis
Metabolomics using mass spectrometry can quantify purine nucleotide levels and isotope tracing can measure flux through de novo and salvage pathways. These methods are essential for assessing pathway activity in cells and tissues.
CRISPR Screening
Genome-wide CRISPR knockout screens can identify genes essential for purine ribonucleotide metabolism and uncover synthetic lethal interactions with metabolic inhibitors. This approach has been used to find new targets in cancer.
Structural Biology and Enzymology
X-ray crystallography and cryo-EM provide detailed structures of purine biosynthetic enzymes, enabling structure-guided inhibitor design. Enzymatic assays measure catalytic activity and kinetics of key enzymes like ATIC and PAICS.
Transcriptomics and Proteomics
RNA-seq and proteomics reveal expression changes in purine metabolic genes under different conditions, such as inflammation or cancer. Post-translational modifications like acetylation can be mapped by mass spectrometry.
How CRISPR Can Be Used to Study GO:0009150 purine ribonucleotide metabolic process
Knockout
CRISPR knockout of genes such as ATIC, PAICS, or IMPDH allows researchers to study loss-of-function phenotypes in cell lines and animal models. For example, ATIC knockout zebrafish exhibit altered muscle atrophy responses to exercise, demonstrating the utility of knockout models in purine metabolism research.
Point Mutation
Introducing specific point mutations in purine metabolic genes, such as those found in patients with ADSL deficiency, can model disease-associated variants and dissect their impact on enzyme activity and pathway flux.
Knock-in
Knock-in of tagged or reporter versions of genes like PAICS enables visualization and purification of the enzyme, facilitating studies of its localization, interactions, and post-translational modifications such as acetylation.
Overexpression
Overexpression of purine biosynthetic genes, such as PRPS1, can mimic pathological states like gout and hyperuricemia, providing models to test therapeutic interventions.
How EDITGENE Supports purine ribonucleotide metabolic process Research
Researchers studying purine ribonucleotide metabolic process-related genes often need to determine whether a candidate gene is causally involved in pathway regulation, disease progression, or drug response. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell and animal models, enabling functional validation and mechanistic studies.
Contact EDITGENE today to design your custom CRISPR model for purine ribonucleotide metabolic process research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| ENTPD4 Knockout HEK293 Cell Line | EDJ-KQ6647 | Human | 9583 | Details Get a Quote |
| ENTPD7 Knockout HEK293 Cell Line | EDJ-KQ13292 | Human | 57089 | Details Get a Quote |
| ENTPD4 Knockout A-549 Cell Line | EDJ-KQ30927 | Human | 9583 | Details Get a Quote |
| ENTPD4 Knockout HCT 116 Cell Line | EDJ-KQ30928 | Human | 9583 | Details Get a Quote |
| ENTPD4 Knockout HeLa Cell Line | EDJ-KQ30929 | Human | 9583 | Details Get a Quote |
| ENTPD7 Knockout A-549 Cell Line | EDJ-KQ42730 | Human | 57089 | Details Get a Quote |
| ENTPD7 Knockout HCT 116 Cell Line | EDJ-KQ42731 | Human | 57089 | Details Get a Quote |
| ENTPD7 Knockout HeLa Cell Line | EDJ-KQ42732 | Human | 57089 | Details Get a Quote |
Displaying Records 1 To 8 Of 8 Records
Frequently Asked Questions About purine ribonucleotide metabolic process
What is GO:0009150?
GO:0009150 is the Gene Ontology term for purine ribonucleotide metabolic process, which encompasses all chemical reactions and pathways involving purine ribonucleotides, including their synthesis, interconversion, and degradation.
What genes are involved in purine ribonucleotide metabolic process?
Key genes include PPAT, GART, PFAS, PAICS, ADSL, ATIC, IMPDH1/2, GMPS, ADSS1/2, APRT, HPRT1, and PRPS1/2, which encode enzymes for de novo synthesis, salvage, and interconversion.
Why is purine ribonucleotide metabolism important for cancer?
Cancer cells require high levels of purine nucleotides for rapid proliferation, and many purine biosynthetic enzymes are overexpressed in tumors, making the pathway a target for anticancer therapy.
How is purine ribonucleotide metabolism regulated?
It is regulated by feedback inhibition, transcriptional control, and post-translational modifications such as acetylation of PAICS by ACSS2, as well as by mTOR signaling.
What diseases are associated with defects in purine metabolism?
Diseases include myogenic hyperuricemia, Lesch-Nyhan syndrome, adenylosuccinate lyase deficiency, and various cancers and inflammatory disorders.
What methods are used to study purine ribonucleotide metabolism?
Common methods include metabolomics, isotope tracing, CRISPR screens, enzyme assays, structural biology, and transcriptomics.
Can CRISPR be used to study purine metabolism genes?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect gene function in purine metabolism, as demonstrated in ATIC knockout zebrafish.
What is the role of ATIC in purine metabolism?
ATIC is a bifunctional enzyme that catalyzes the final two steps of de novo purine biosynthesis, and its knockout in zebrafish affects muscle atrophy and exercise response.
How does PAICS acetylation affect purine biosynthesis?
Acetylation of PAICS by ACSS2 reduces purine biosynthesis and drives the senescence-associated secretory phenotype, linking metabolic state to pathway regulation.
What are purinosomes?
Purinosomes are multienzyme complexes of de novo purine biosynthesis enzymes that channel intermediates to enhance pathway efficiency.
Conclusion
Purine ribonucleotide metabolic process (GO:0009150) is a fundamental biological pathway that supplies nucleotides for DNA/RNA synthesis, energy metabolism, and signaling. Its dysregulation is implicated in cancer, inflammatory diseases, and inherited metabolic disorders. Advances in CRISPR gene editing and metabolomics have accelerated our understanding of the pathway and opened new avenues for therapeutic intervention. EDITGENE provides comprehensive CRISPR services to support research on purine metabolism genes, from knockout to overexpression models and library screening.
References
- 1. Pareek V et al.. 2021. Human de novo purine biosynthesis.. Crit Rev Biochem Mol Biol 56(1):1-16 PMID: 33179964
- 2. Linden J et al.. 2019. Purine Release, Metabolism, and Signaling in the Inflammatory Response.. Annu Rev Immunol 37:325-347 PMID: 30676821
- 3. Yang L et al.. 2025. ACSS2 drives senescence-associated secretory phenotype by limiting purine biosynthesis through PAICS acetylation.. Nat Commun 16(1):2071 PMID: 40021646
- 4. Sharma MF et al.. 2024. Carboxylation in de novo purine biosynthesis.. Methods Enzymol 708:389-424 PMID: 39572148
- 5. Yamasaki T et al.. 1996. [Myogenic hyperuricemia].. Nihon Rinsho 54(12):3343-8 PMID: 8976117
- 6. Belfon KKJ et al.. 2023. Structure-Guided Discovery of N(5)-CAIR Mutase Inhibitors.. Biochemistry 62(17):2587-2596 PMID: 37552766
- 7. Peng Z et al.. 2025. Aerobic exercise ameliorates skeletal muscle atrophy in atic knockout zebrafish through the oxidative phosphorylation pathway.. Free Radic Biol Med 238:653-668 PMID: 40623538
- 8. Murray JM et al.. 2009. Targeting the purinome.. Methods Mol Biol 575:47-92 PMID: 19727611
